The Trouble with CBD Oil

Published on Jun 12, 2018
· DOI :10.1159/000489287
Arno Hazekamp1
Estimated H-index: 1
In just a few years, cannabidiol (CBD) has become immensely popular around the world. After initially being discovered as an effective self-medication for Dravet syndrome in children, CBD is now sold and used to treat a wide range of medical conditions and lifestyle diseases. The cannabinoid CBD, a non-psychoactive isomer of the more infamous tetrahydrocannabinol (THC), is available in a growing number of administration modes, but the most commonly known is CBD oil. There are currently dozens, if not hundreds, of producers and sellers of CBD oils active in the market, and their number is increasing rapidly. Those involved vary from individuals who prepare oils on a small scale for family and (Facebook) friends to compounding pharmacies, pharmaceutical companies, and licensed cannabis producers. Despite the growing availability of CBD, many uncertainties remain about the legality, quality, and safety of this new “miracle cure.” As a result, CBD is under scrutiny on many levels, ranging from national health organizations and agricultural lobbyists to the WHO and FDA. The central question is whether CBD is simply a food supplement, an investigational new medicine, or even a narcotic. This overview paper looks into the known risks and issues related to the composition of CBD products, and makes recommendations for better regulatory control based on accurate labeling and more scientifically supported health claims. The intention of this paper is to create a better understanding of the benefits versus the risks of the current way CBD products are produced, used, and advertised.
  • References (25)
  • Citations (10)
📖 Papers frequently viewed together
1 Author (Michael Crane)
1 Author (Jennifer Grebow)
1 Citations
78% of Scinapse members use related papers. After signing in, all features are FREE.
#1Eric GroceH-Index: 1
159 CitationsSource
#1Nick JikomesH-Index: 1
#2Michael Zoorob (Harvard University)H-Index: 3
The majority of adults in the U.S. now have state-legal access to medical or recreational cannabis products, despite their federal prohibition. Given the wide array of pharmacologically active compounds in these products, it is essential that their biochemical profile is measured and reported to consumers, which requires accurate laboratory testing. However, no universal standards for laboratory testing protocols currently exist, and there is controversy as to whether all reported results are le...
17 CitationsSource
The biological effects of cannabinoids, the major constituents of the ancient medicinal plant Cannabis sativa (marijuana) are mediated by two members of the G-protein coupled receptor family, cannabinoid receptors 1 (CB1R) and 2. The CB1R is the prominent subtype in the central nervous system (CNS) and has drawn great attention as a potential therapeutic avenue in several pathological conditions, including neuropsychological disorders and neurodegenerative diseases. Furthermore, cannabinoids als...
44 CitationsSource
#2J. ZeylandH-Index: 10
Last. Agnieszka NowakH-Index: 5
view all 4 authors...
To date, cannabinoids have been allowed in the palliative medicine due to their analgesic and antiemetic effects, but increasing number of preclinical studies indicates their anticancer properties. Cannabinoids exhibit their action by a modulation of the signaling pathways crucial in the control of cell proliferation and survival. Many in vitro and in vivo experiments have shown that cannabinoids inhibit proliferation of cancer cells, stimulate autophagy and apoptosis, and have also a potential ...
12 CitationsSource
#1Allegra Leghissa (UTA: University of Texas at Arlington)H-Index: 3
Last. Kevin A. Schug (UTA: University of Texas at Arlington)H-Index: 28
view all 3 authors...
Cannabis has garnered a great deal of new attention in the past couple of years in the United States due to the increasing instances of its legalization for recreational use and indications for medicinal benefit. Despite a growing number of laboratories focused on cannabis analysis, the separation science literature pertaining to the determination of cannabis natural products is still in its infancy despite the plant having been utilized by humans for nearly 30 000 years and it being now the mos...
17 CitationsSource
#1Philip McGuireH-Index: 110
#2Philip Robson (University of Oxford)H-Index: 20
Last. Stephen Wright (GW Pharmaceuticals)H-Index: 11
view all 8 authors...
Objective:Research in both animals and humans indicates that cannabidiol (CBD) has antipsychotic properties. The authors assessed the safety and effectiveness of CBD in patients with schizophrenia.Method:In an exploratory double-blind parallel-group trial, patients with schizophrenia were randomized in a 1:1 ratio to receive CBD (1000 mg/day; N=43) or placebo (N=45) alongside their existing antipsychotic medication. Participants were assessed before and after treatment using the Positive and Neg...
86 CitationsSource
Abstract Objectives: The aim of this review is to discuss cannabinoids from a preclinical and clinical oncological perspective and provide the audience with a concise, retrospective overview of the most significant findings concerning the potential use of cannabinoids in cancer treatment. Methods: A literature survey of medical and scientific databases was conducted with a focus on the biological and medical potential of cannabinoids in cancer treatment. Results: Cannabis sativa is a plant rich ...
12 CitationsSource
#1Michelle SextonH-Index: 6
#2Kyle SheltonH-Index: 1
Last. Mike WestH-Index: 1
view all 4 authors...
A recent cannabis use survey revealed that 60% of cannabis users rely on smelling the flower to select their cannabis. Olfactory indicators in plants include volatile compounds, principally represented by the terpenoid fraction. Currently, medicinal- and adult-use cannabis is marketed in the United States with relatively little differentiation between products other than by a common name, association with a species type, and Δ-9 tetrahydrocannabinol/cannabidiol potency. Because of this practice,...
9 CitationsSource
BACKGROUND: Despite the introduction of new antiepileptic drugs (AEDs), the quality of life and therapeutic response for patients with epilepsy remain unsatisfactory. In addition, whilst several antiepileptic drugs (AEDs) have been approved and consequently marketed in recent years, little is known about their long-term safety and tolerability. Availability of the newest AEDs, characterized by improved pharmacokinetic profiles, has positively impacted the treatment approach for patients with par...
3 CitationsSource
#1Orrin Devinsky (NYU: New York University)H-Index: 82
#2Jh Cross (UCL: University College London)H-Index: 46
Last. Stephen Wright (GW Pharmaceuticals)H-Index: 11
view all 9 authors...
BackgroundThe Dravet syndrome is a complex childhood epilepsy disorder that is associated with drug-resistant seizures and a high mortality rate. We studied cannabidiol for the treatment of drug-resistant seizures in the Dravet syndrome. MethodsIn this double-blind, placebo-controlled trial, we randomly assigned 120 children and young adults with the Dravet syndrome and drug-resistant seizures to receive either cannabidiol oral solution at a dose of 20 mg per kilogram of body weight per day or p...
261 CitationsSource
Cited By10
Purpose: The use of veterinary low tetrahydrocannabinol (THC) Cannabis sativa (ie, hemp) products has increased in popularity for a variety of pet ailments. Low-THC Cannabis sativa is federally legal for sale and distribution in the USA, and the rise in internet commerce has provided access to interested consumers, with minimal quality control. Materials and Methods: We performed an internet word search of "hemp extract and dog" or "CBD product and dog" and analyzed 29 products that were using l...
Cannabis ist die weltweit am haufigsten konsumierte Droge. Medizinisches Cannabis, naturliche und synthetische Cannabinoide finden zunehmend Akzeptanz in der Medizin und werden von vielen Patienten zur Linderung von Schmerzen und anderer Beschwerden verwendet. Erste klinische Daten weisen auf einen erhohten Bedarf an Anasthetika und Analgetika bei Cannabiskonsumenten hin. Der Artikel fasst daher die aktuelle Literatur zu Auswirkungen und potenziellen Risiken von Cannabis/Cannabinoiden fur die pe...
#1Ariane Barbacki (MUHC: McGill University Health Centre)
#1Ariane Barbacki (MUHC: McGill University Health Centre)
Last. Mary-Ann Fitzcharles (MUHC: McGill University Health Centre)H-Index: 35
view all 2 authors...
Purpose of the review Pain is a prevailing symptom in osteoarthritis (OA) and greatly impacts quality of life. Pain-relieving strategies over thousands of years have included opioids and cannabinoids but require critical evaluation of efficacy and risks in this twenty-first century. This review will examine the most up-to-date evidence for use of these two categories of drugs.
#1Mari Kannan Maharajan (International Medical University)H-Index: 5
#2Yu Jing Yong (International Medical University)
Last. Kai Xian Yap (International Medical University)
view all 8 authors...
Globally, chronic pain is a major therapeutic challenge and affects more than 15% of the population. As patients with painful terminal diseases may face unbearable pain, there is a need for more potent analgesics. Although opioid-based therapeutic agents received attention to manage severe pain, their adverse drug effects and mortality rate associated with opioids overdose are the major concerns. Evidences from clinical trials showed therapeutic benefits of cannabis, especially delta-9-tetrahydr...
#1Dirk W. LachenmeierH-Index: 42
Last. Patrick DielH-Index: 1
view all 2 authors...
Cannabidiol (CBD) is a non-psychoactive cannabinoid, widely marketed to athletes for claimed effects such as decreased anxiety, fear memory extinction, anti-inflammatory properties, relief of pain and for post-exercise recovery. The World Anti-Doping Agency (WADA) has excluded CBD from its list of prohibited substances. Nevertheless, caution is currently advised for athletes intending to use the compound—except CBD, all other cannabinoids are still on the prohibited list. CBD products, specifica...
1 CitationsSource
#1Mary-Ann Fitzcharles (MUHC: McGill University Health Centre)H-Index: 35
#2Winfried Häuser (TUM: Technische Universität München)H-Index: 51
Purpose Interest in cannabinoids as a therapy in rheumatic diseases has grown exponentially. With legalization of medical and recreational cannabis in many jurisdictions worldwide, patients have easier access and opportunity to explore medicinal use. We report on the evidence for effect of cannabinoids in rheumatic diseases and critically address the current challenges surrounding use.
Cannabis sativa L. is a plant long used for its textile fibers, seed oil, and oleoresin with medicinal and psychoactive properties. It is the main source of phytocannabinoids, with over 100 compounds detected so far. In recent years, a lot of attention has been given to the main phytochemicals present in Cannabis sativa L., namely, cannabidiol (CBD) and Δ9-tetrahydrocannabinol (THC). Compared to THC, CBD has non-psychoactive effects, an advantage for clinical applications of anti-tumor benefits....
5 CitationsSource
#1Stuart FarquharsonH-Index: 5
#1Stuart FarquharsonH-Index: 13
Last. Chetan ShendeH-Index: 12
view all 4 authors...
During the past decade, the ability of surface-enhanced Raman spectroscopy (SERS) to measure extremely low chemical concentrations, such as mg/L and below, and the availability of hand-held Raman spectrometers, has led to a significant growth in the number and variety of applications of SERS to real-world problems. Most of these applications involve the measurement of drugs, such as quantifying medication in patients, identifying illicit drugs in impaired drivers, and more recently, identifying ...
#1S. Steenson (British Nutrition Foundation)
#2L. Chambers (British Nutrition Foundation)H-Index: 4